Fintel reports that on October 17, 2024, Bernstein initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Outperform ...

Gilead Sciences GILD has outperformed the market over the past 20 years by 3.74% on an annualized basis producing an average ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has ...

Fintel reports that on October 7, 2024, Wells Fargo upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...

PORTLAND, CA, UNITED STATES, October 7, 2024 /EINPresswire / -- According to the report, the global cancer gene therapy <a target=_blank href=ht ...

According to Gilead Sciences, the data from the two trials will now be used to support a series of global regulatory filings ... needs to be in place to reach at-risk populations and make sure ...

Injectable Drug Market. The global injectable drug market is poised for significant growth, with an estimated valuation of ...

Hetero on Wednesday announced a new partnership with Gilead Sciences Ireland UC to manufacture and distribute lenacapavir in 120 primarily low- and lower- middle income countries (LMICs).

Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752) providing an overview of the efficacy and safety of twice-yearly lenacapavir ...

The projected annual revenue for Gilead Sciences is 26,909MM ... first therapies to the market. Through global partnerships, Gilead's medicines today reach millions of people in low- and middle ...